Navigation Links
BioMed Central launches Biology Direct

BioMed Central is pleased to announce the launch of Biology Direct, a new online open access journal with a novel system of peer review. Biology Direct will operate completely open peer review, with named peer reviewers' reports published alongside each article. The journal also takes the innovative step of requiring that the author approach Biology Direct Editorial Board members directly to review the manuscript.

The journal, available online at www.biology-direct.com, launches with publications in the fields of Systems Biology, Computational Biology, and Evolutionary Biology, with an Immunology section to follow soon. Biology Direct considers original research articles, hypotheses, and reviews and will eventually cover the full spectrum of biology.

Biology Direct is led by Editors-in-Chief David J Lipman, Director of the National Center Biotechnology Information (NCBI) a division of the National Library of Medicine (NLM) at NIH, USA; Eugene V Koonin, Senior Investigator at NCBI; and Laura Landweber, Associate Professor at Princeton University, Princeton, NJ, USA. Lipman has long been interested in open access and has been central in the development of PubMed, GenBank and PubMed Central, the NLM's open access repository for literature in the life sciences.

Lipman and Koonin, speaking on the eve of the journal's launch, explain the motivation for establishing Biology Direct:

"We were compelled to launch this experiment because, while scientific publishing cannot be effective without peer review, we saw flaws in the current, predominantly, anonymous review system that run too deep to be rectified without a radical departure from the standard practices. It is our hope that the open peer-review system of Biology Direct, which allows a direct relationship between authors and reviewers, will be a major advantage for everyone involved - authors, readers, and reviewers alike."

Biology Dir
'"/>

Source:BioMed Central


Page: 1 2 3

Related biology news :

1. BioMed Central welcomes the new National Institutes of Health public access policy
2. Impressive new Impact Factors for BioMed Centrals open-access journals
3. Ariadne Genomics Announces the Release of PathwayStudio?Central, Client-Server Software for Biological Pathway Analysis
4. Parts of the Caribbean and Central America are likely to have less summer rain
5. UCLA launches $20 million stem cell institute to investigate HIV, cancer and neurological disorders
6. UNC launches study of liver injury caused by drugs
7. DOE JGI launches IMG public online microbial genome data clearinghouse
8. NIEHS launches website with information for assessing environmental hazards from Hurricane Katrina
9. NIH launches comprehensive effort to explore cancer genomics
10. Virginia Bioinformatics Institutes launches microbial database
11. Protein structure initiative launches new resources for the scientific community

Post Your Comments:
(Date:11/24/2009)...akened and flabby arteries from collapsing have be...tents are no longer needed -- once the arteries ar...y, doctors had no choice but to leave them in plac...ty,s Department of Biomedical Engineering has deve...ries drugs where they,re needed, then dissolves. ,...
(Date:11/24/2009)...rctica has long held secrets of the earth,s histor...ere has been very little information on the enviro...for millions of years. Now, a team of researchers ...unded to the tune of $10 million dollars by the Na...ottom of things literally. These scientists will ...
(Date:11/23/2009)...rch presents strong evidence that the "synergistic...affic-related pollution and indoor endotoxin cause...her exposure alone. , Environmental health sci...ge of Medicine have shown that children exposed to... indoor endotoxin during early life are six times ...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile 59967 1Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile 59967 2Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile 59967 3Rotavirus Vaccine Cutting Infection Rates Among Kids 59964 1Rotavirus Vaccine Cutting Infection Rates Among Kids 59964 2Syphilis survey reveals need for accurate testing for early infection 59960 1
...r an important and longstanding question about the...tients have high levels of a brain protein because...ear it from their brains quickly enough? , Resear... (ADRC) at Washington University School of Medicin...ensitive way to monitor the production and clearan...
...ered that a recently identified protein critical f...sm to keep its repairs accurate. , The protein, ... proteins known as DNA polymerases that are vital ...while other DNA-repair proteins insure their accur...ns or accessory molecules, this protein maintains ...
...asbro Children’s Research Center and Brown Medical...atest risk for HIV. Amongst a group of high-risk t... for the disease (those who engaged in the most un...ental health problems. , Prior studies have found ...h mental health issues and other high-risk behavio...
Other Biology News:Production of key Alzheimer's protein monitored for first time in humans 2Production of key Alzheimer's protein monitored for first time in humans 3Unusual mechanism keeps repair protein accurate 2Unusual mechanism keeps repair protein accurate 3New HIV study identifies high-risk subgroups of adolescents 2New HIV study identifies high-risk subgroups of adolescents 3
(Date:11/23/2009)...3/PRNewswire/--Frost&Sullivan,theGrowthPartner...tingleadershipandinnovationThursday,November19,200...theldinSanAntonio,Texas. ,, (Logo: http://www.n...eHealthcareInnovationAwardsaregiventocompaniesthat...nagementofhealthcare.Suchcompanieshaveshownsuccess...
(Date:11/23/2009)...re-FirstCall/--CornerstoneTherapeuticsInc.(Nasdaq:...quiring,developingandcommercializingsignificantpro...odayannouncedthatCraigA.Collard,PresidentandChiefE...atthe21stAnnualPiperJaffrayHealthCareConferenceat3...eHotelinNewYorkCity. ,, Aliveaudioandarchivedwe...
(Date:11/20/2009)...ies have an opportunity to take the lead in two sm...iversity of Valencia (UV), working together with t... fabric of the Spanish biotechnology industry. The...rs have more clout than those in English-speaking ...d plants has been overlooked by the leading countr...
(Date:11/20/2009)...ewswire-FirstCall/ -- Dendreon Corporation (Nasdaq...rug Administration (FDA) provided written acknowle...se Application (BLA) for PROVENGE® (sipuleuce... a Prescription Drug User Fee Act (PDUFA) date of ...reon,s amended BLA. Dendreon is seeking licensure...
Breaking Biology Technology:Excellence in Healthcare Innovation Recognized by Frost & Sullivan 2Excellence in Healthcare Innovation Recognized by Frost & Sullivan 3Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Spanish biotechnology should focus on food and plant sectors to be more competitive 2Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3
...l 25 CV Therapeutics,Inc. (Nasdaq: CVTX ) today ...nded March 31, 2008., For the quarter ended March...9 million, or $0.53 per share. This compares to a ... the prior quarter ended December 31, 2007,and $55...er in 2007., For the quarter ended March 31, 2008...
...ntists and Collaborators Publish Study in Science,...bH, the,leading developer of RAFT intervention the...per in Science demonstrating a potential novel str...and other diseases by targeting,discrete sub-compa...nducted,by JADO scientists together with several a...
...lif., April 24 ,Exelixis, Inc. (Nasdaq: EXEL ) an...t and chief executive officer of Exelixis, will pr...ugged Conference at 3:40 p.m. ET/12:40,p.m. PT on ...s updates to,the company,s development pipeline an...ebcast and may be accessed in the Event,Calendar p...
Other Biology Technology:CV Therapeutics Reports 2008 First Quarter Financial Results 2CV Therapeutics Reports 2008 First Quarter Financial Results 3CV Therapeutics Reports 2008 First Quarter Financial Results 4CV Therapeutics Reports 2008 First Quarter Financial Results 5Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 2Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 3Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 4
Rabbit Anti-NMDAR1 C2' Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Coronin / CORO1C Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-Human Retinoic Acid-Induced 3 (RAI3 / RAIG1) Polyclonal Antibody, Unconjugated from IMGENEX
GIBCO Sf-900 Medium (1.3X) liquid from Invitrogen
Biology Products: